These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12408547)

  • 1. A cost analysis of the prostaglandin analogs.
    Mick AB; Gonzalez S; Dunbar MT; McSoley JJ
    Optometry; 2002 Oct; 73(10):614-9. PubMed ID: 12408547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily cost of glaucoma medications in China.
    Gao Y; Wu L; Li A
    J Glaucoma; 2007; 16(7):594-7. PubMed ID: 18091176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF; Tan J; Kotak S
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of instillation methods for prostaglandin medications.
    Fiscella R; Wilensky JT; Chiang TH; Walt JG
    J Ocul Pharmacol Ther; 2006 Dec; 22(6):477-82. PubMed ID: 17238816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost considerations of the new fixed combinations for glaucoma medical therapy.
    Ventura MP; Saheb NE; Solari HP; Saraiva VS; Vianna RN; Burnier MN
    J Clin Pharm Ther; 2005 Jun; 30(3):251-4. PubMed ID: 15896242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.
    Walt JG; Lee JT
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S36-44. PubMed ID: 15016560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.
    Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
    Clin Drug Investig; 2007; 27(12):819-25. PubMed ID: 18020539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The more favourable cost/effectiveness ratio of latanoprost vs bimatoprost and travoprost when using normally for treatment of glaucoma].
    Soto J
    Arch Soc Esp Oftalmol; 2005 Jan; 80(1):9-10; author reply 10. PubMed ID: 15692888
    [No Abstract]   [Full Text] [Related]  

  • 11. [Considerations about administration angle of prostaglandin analogs].
    Estacia P; Tognon T
    Arq Bras Oftalmol; 2008; 71(5):684-8. PubMed ID: 19039464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective.
    Tuil E; Hommer AB; Poulsen PB; Christensen TL; Buchholz P; Walt J; Holmstrom S
    Int J Clin Pract; 2005 Sep; 59(9):1011-6. PubMed ID: 16115174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of glaucoma medications.
    Rylander NR; Vold SD
    Am J Ophthalmol; 2008 Jan; 145(1):106-13. PubMed ID: 18154755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.
    Queen JH; Feldman RM; Lee DA
    Am J Ophthalmol; 2016 Mar; 163():70-74.e1. PubMed ID: 26596398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment.
    Rodrigues Mde L; Felipe Crosta DP; Soares CP; Deghaide NH; Duarte R; Sakamoto FS; Furtado JM; Paula JS; Donadi EA; Soares EG
    J Glaucoma; 2009 Mar; 18(3):197-200. PubMed ID: 19295371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
    Aptel F; Cucherat M; Denis P
    J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of additivity to prostaglandin analogs: fixed and unfixed combinations.
    Tabet R; Stewart WC; Feldman R; Konstas AG
    Surv Ophthalmol; 2008 Nov; 53 Suppl1():S85-92. PubMed ID: 19038627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
    Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S28-33. PubMed ID: 16389058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.